Ajay Major, MD, MBA

@majorajay

Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky

230 Siguiendo574 Seguidores507 Publicaciones

Bluesky

¿Es tu perfil?Reclámalo y majorajay.dirty.social es tuyo.Reclamar perfil

Ajay Major, MD, MBA@majorajay· 3d

Mosun/pola in R/R MCL post BTKi @BloodPortfolio - 42 pts, 67% high Ki67, 48% TP53mut, 26% prior CAR - ORR 88% (CR 79%), post-CAR ORR 91%, TP53mut ORR 100% - mPFS 18.6 mos, mOS 20.7 mos - CRS 43% (all G1-2), ICANS 7% (all G1-2) - 5 (12%) G5 infection-related AEs (3 COVID, 1 WNV, 1 PNA) #oncsky 1/2

Ajay Major, MD, MBA@majorajay· 5d

Congratulations to my mentee Dr. Elisa Hofmeister @cuinternalmed.bsky.social on publication of this comprehensive review of patient-reported outcomes from novel lymphoma immunotherapies. Harmonized PRO and tolerability measurement frameworks are needed. #lymsm pubmed.ncbi.nlm.nih.gov/42565955/

Ajay Major, MD, MBA@majorajay· 9d

Congratulations to my mentee Dr. @vpizzuti.bsky.social on this analysis of 2 years of PRO data in CAR-T recipients, now published @bloodjournals.hematology.org. CAR-T confers long-term QoL benefits, and worsening patient-reported fatigue at D+15 may predict subsequent response as a "PRO-marker."

Ajay Major, MD, MBA@majorajay· 10d

Fixed-duration ven after cBTKi progression in CLL @bloodjournals.hematology.org - 79 pts, 71% VR, 82% 2/3L, 20% TP53mut - ORR 78% (CR 41%) - 18-mo PFS 79%, TTNT 80%, OS 84% - VR subgroup: 18-mo PFS 78%, OS 87% - VO subgroup too small Good RW data to support tx sequencing. #oncsky #medsky

Ajay Major, MD, MBA@majorajay· Jul 5

TME may explain pola-R-CHP benefit in DLBCL #lymsm - post-hoc RNAseq analysis across 3 RCTs: >1200 pts - low M1-like macrophage infiltration = worse PFS/OS with R/GCHOP, but NOT prognostic with pola-R-CHP - in M1-low pts, pola-R-CHP improved PFS v R-CHOP: HR 0.59 1/2

Ajay Major, MD, MBA@majorajay· Jun 23

Speaking today at the IVI PCORI-funded Convening on time toxicity in patients with cancer. Excited to highlight our latest publication on measuring time toxicity as a patient-reported outcome: academic.oup.com/oncolo/artic... #lymsm #oncsky

Ajay Major, MD, MBA@majorajay· Jun 22

5-year CLL13/GAIA follow-up: - 5-yr PFS: GIV 81%, GV 70%, RV 57%, CIT 51% - no OS differences - figure has uIGHV (B) vs mIGHV (C) - cardiac AEs highest with GIV - GV/RV had faster QoL improvements vs CIT; GIV QoL gains occurred later (more tx-related side effects) 1/

Ajay Major, MD, MBA@majorajay· Jun 16

Super important data: PROs for R-pola-glo unfit 1L LBCL #lymsm - 80 pts, med age 80, 91% frail - high PRO completion >80% Despite frailty, clinically-meaningful QoL improvements: - global QoL during tx; 44% w/ sig improvement by C4 - physical function/fatigue maintained - emotional QoL improved 1/

Ajay Major, MD, MBA@majorajay· Jun 15

- If CR: 1-yr PFS 76%, 1-yr OS 77% - CRS 33% (G3+ 4.6%), ICANS 13% (G3+ 0.6%) - ICU admission 17%! RW outcomes inferior to trial results, mostly due to high-risk disease & trial-ineligible patients. However, CRs can be durable; need to identify predictors of response. #lymsm

Ajay Major, MD, MBA@majorajay· Jun 15

RW epcor R/R LBCL outcomes (CUBIC Consortium): - 157 pts, 55% prior CAR, 46% trial ineligible - ORR 50%, CR 32% - mPFS 3.5 mo, mOS OS 7.6 mo - 1-year PFS 29%, 1-year OS 38% - ⬇️survival: poor PS,⬆️LDH, refractory, trial ineligible 1/ #lymsm pubmed.ncbi.nlm.nih.gov/42263668/

Ajay Major, MD, MBA@majorajay· May 31

Frontline H. pylori eradication for extragastric ENMZL #lymsm - 26 pts, 46% conjunctival, 19% parotid - ORR 65% (CR 39%, PR 27%), time to CR 6 mos - 7-yr EFS 77%, OS 96% - HP+ dx with better responses (obv), t(11;18) less responses Provocative evidence re: HP+ in non-gastric sites...

Ajay Major, MD, MBA@majorajay· May 28

Fixed-duration SC mosun older/unfit 1L DLBCL #ASCO26 - median age 83 (71-101!), 53% IPI 3-5 - ORR 74%, CR 59% - 12-mo PFS 71%, OS 75% - CRS 12% (all G1-2), 49% infx (16% G3), 8% G5 AEs - PROs: 53% w/ improvements in lymphoma sx #lymsm

Ajay Major, MD, MBA@majorajay· May 24

CD3xCD20 BsAb secondary CNS lymphoma (CUBIC Consortium) - 28 pts, most glofi, 64% active CNS dx, 64% prior CAR - active CNS: ORR 56% (CR 33%), CNS ORR 65% (CR 35%), 6-mo PFS 43% (CNS-PFS 53%) - no PD among pts achieving CR - responses in LM dx & post-CAR - 25% ICANS (incl G3-4) #lymsm #oncsky

Ajay Major, MD, MBA@majorajay· May 23

Time-limited & less frequent BsAb dosing translates into meaningful reductions in time toxicity, both in the clinic and at home. Time tox is a vital #lymsm patient-centered endpoint! Grateful to the L-THORs (Lymphoma-Translational Health Outcomes Researchers) for making this study happen! #oncsky

Ajay Major, MD, MBA@majorajay· May 23

Our study on patient-reported time toxicity of BsAb in R/R FL & DLBCL #lymsm - 120 pts actively receiving BsAb tx - fixed-duration BsAb (glofi, mosun) = less healthcare contact days & ~50% less time burden (vs epco) - no difference in infusion time between IV and SQ academic.oup.com/oncolo/advan...

Ajay Major, MD, MBA@majorajay· May 21

Congratulations to our Major Lab member Keegan Carroll on his abstract at @accordsresearch.bsky.social COPRH Con on patient-reported financial toxicity in patients with lymphoma. Look out for the future manuscript! #lymsm @cucancercenter.bsky.social @cuanschutz.bsky.social @cuhematology.bsky.social

Ajay Major, MD, MBA@majorajay· May 21

Eager to be presenting at the @accordsresearch.bsky.social COPRH Con today on pragmatic use of PROs in cancer research! Joined by Drs. Sarah Tevis, Tyler Buckner, & Allison L'Hotta. #PRO #QoL cc @cuanschutz.bsky.social @cucancercenter.bsky.social @cuhematology.bsky.social

Ajay Major, MD, MBA@majorajay· May 6

ctDNA TRANSFORM #lymsm - MRDneg = longer EFS at all timepoints - more pts achieved MRDneg with liso-cel v SOC - among MRDneg pts liso-cel ⬆️ EFS, PFS, DOR - MRD re-emergence 1 yr: 0/20 liso-cel v 9/15 ASCT - ctDNA prognostic independent of PET Role for ctDNA+PET post-CAR? ascopubs.org/doi/pdf/10.1...

Ajay Major, MD, MBA@majorajay· May 6

NAVD real-world outcomes #lymsm - 327 pts, med age 37, 24% ≥60 yrs - ORR 94% (CR 86%) - 1-yr PFS 94.5%, OS 99.7% - irAEs in 29% (9% G3+) - febrile neutropenia 10%, infections 25% (10% G3+) RW efficacy mirrors S1826, tho notably⬆️ infections (despite GCSF) & irAEs. pmc.ncbi.nlm.nih.gov/articles/PMC...

Ajay Major, MD, MBA@majorajay· Apr 22

Mosun/pola R/R MCL #lymsm - 42 pts, 26% prior CAR, 48% TP53mut - ORR 88% (CR 79%) - mPFS 19 mos, mOS 21 mos - prior CAR: ORR 91% (CR 82%) - 43% CRS (all G1-2), 5 G5 AEs, all infection-related Great activity in TP53mut and post-CAR in challenging R/R setting. ashpublications.org/blood/articl...

Ajay Major, MD, MBA@majorajay· Apr 21

Come join us on Saturday, May 2 for the @bloodcancerunited.bsky.social 2026 Rocky Mountain Blood Cancer Conference! I'll be speaking about Waldenström macroglobulinemia and novel therapeutic approaches on the horizon. #lymsm #wmsm bloodcancerunited.org/RMBCC26

Ajay Major, MD, MBA@majorajay· Apr 16

Stage IA NLPHL outcomes - 779/2243 pts Stage IA - completely resected: better PFS if +RT - unresected: R monotx & ABVD with worse PFS as compared to RT +/- ABVD - not enough N to analyze R-CHOP RT alone great option in both resected & unresected dx. #lymsm ashpublications.org/bloodadvance...

Ajay Major, MD, MBA@majorajay· Mar 10

New anatomic classification R/R SCNSL - 162 pts, 42 with both CNS+systemic dx - leptomeningeal dx = inferior OS in MV model - 4 subtypes w/ distinct PFS & OS: parenchymal +/- systemic and LM +/- systemic (see KM curve) Useful schema in future trials. #lymsm onlinelibrary.wiley.com/doi/10.1002/...

Ajay Major, MD, MBA@majorajay· Mar 9

Glofitamab CNS penetration @bloodadvances.bsky.social - 8 PCNSL/SCNSL, 7 LBCL, 1 BL - 3/8 CRS (all G1-2), no ICANS - 7/8 response (4 CR, 3 PR) - 2 PCNSL durable CRs - CSF: +glofi with activity in vitro Bridging to CAR for SCNSL or even monotx for PCNSL. #lymsm ashpublications.org/bloodadvance...

Ajay Major, MD, MBA@majorajay· Mar 9

Tazemetostat pulled from the market this morning due to secondary malignancy risks seen in the SYMPHONY-1 trial. #lymsm

Ajay Major, MD, MBA@majorajay· Feb 17

We found ORR 70 (CR 45%) of bispecifics after CAR-T, with mPFS 8.9 mos and median DOR and OS not reached. Patients with late post-CAR relapse (>6 months) who were treated with CD20 bispecifics had better outcomes. Infections were common, highlighting cumulative immunosuppression. #lymsm

Ajay Major, MD, MBA@majorajay· Feb 6

Axi-cel can now be used for R/R PCNSL! HT @samyamshon.bsky.social #lymsm #tcellrx

Ajay Major, MD, MBA@majorajay· Feb 3

Infx post CD20 bispecifics @bloodadvances.bsky.social - 122 pts - 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV) - 76% cumulative incidence infx at 2 yrs - 8% G5 infx at 1 year Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm ashpublications.org/bloodadvance...

Ajay Major, MD, MBA@majorajay· Jan 29

Hoping I have favor with the kiln deities! #pleasedontbreak #pottery

Ajay Major, MD, MBA@majorajay· Jan 29

Elated to be presenting our MAGIC-ONC vascular access appropriateness recommendations in patients with cancer to the @hms-mi.bsky.social consortium today! Be sure to read the full paper published @annalsofim.bsky.social: www.acpjournals.org/doi/10.7326/... #medsky #oncsky cc @davidpaje.bsky.social